Epilepsy trials recruiting in District of Columbia

All Epilepsy trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
  NCT01694940 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
  NCT05135091 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · District of Columbia: Washington D.C.